Accumulating data have also indicated that adiponectin may act as an anti-angiogenic factor in the tumor microenvironment by the decreased expression of CD31, VEGFB, and VEGFD and interleukin-12 (IL-12) activity modulation (Figure 1) [18,50,51]. The gene discussed is ADIPOQ; the disease is neoplasm.